New hormone therapies before surgery may improve outcomes in high-risk prostate cancer
byWolters Kluwer HealthTime to BCR in the neo-RP and RP cohorts after IPTW. The number of participants at risk are based on unweighted population. Credit:Journal of Urology(2022). DO
Updated on: January 04,2024
9

New hormone therapies before surgery may improve outcomes in high-risk prostate cancer
byWolters Kluwer HealthTime to BCR in the neo-RP and RP cohorts after IPTW. The number of participants at risk are based on unweighted population. Credit:Journal of Urology(2022). DO
Updated on:January 04,2024
9
